title: Collaborative Effort for a Centralized Worldwide Tuberculosis Relational Sequencing Data Platform.
abstract: Continued progress in addressing challenges associated with detection and management of tuberculosis requires new diagnostic tools. These tools must be able to provide rapid and accurate information for detecting resistance to guide selection of the treatment regimen for each patient. To achieve this goal, globally representative genotypic, phenotypic, and clinical data are needed in a standardized and curated data platform. A global partnership of academic institutions, public health agencies, and nongovernmental organizations has been established to develop a tuberculosis relational sequencing data platform (ReSeqTB) that seeks to increase understanding of the genetic basis of resistance by correlating molecular data with results from drug susceptibility testing and, optimally, associated patient outcomes. These data will inform development of new diagnostics, facilitate clinical decision making, and improve surveillance for drug resistance. ReSeqTB offers an opportunity for collaboration to achieve improved patient outcomes and to advance efforts to prevent and control this devastating disease.
authors.affiliation: Division of Tuberculosis Elimination, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia.
authors.forename: Angela M
authors.initials: AM
authors.lastname: Starks
authors.affiliation: Critical Path Institute, Tucson, Arizona.
authors.forename: Enrique
authors.initials: E
authors.lastname: Avilés
authors.affiliation: Istituti di Ricovero e Cura a Carattere Scientifico, San Raffaele Scientific Institute, Milan, Italy.
authors.forename: Daniela M
authors.initials: DM
authors.lastname: Cirillo
authors.affiliation: Foundation for Innovative New Diagnostics, Geneva, Switzerland.
authors.forename: Claudia M
authors.initials: CM
authors.lastname: Denkinger
authors.affiliation: Foundation for Innovative New Diagnostics, Geneva, Switzerland.
authors.forename: David L
authors.initials: DL
authors.lastname: Dolinger
authors.affiliation: Centre for Ethical, Social, and Cultural Risk, Li Ka Shing Knowledge Institute of St Michael's Hospital, Toronto, Ontario, Canada.
authors.forename: Claudia
authors.initials: C
authors.lastname: Emerson
authors.affiliation: Bill & Melinda Gates Foundation, Seattle, Washington.
authors.forename: Jim
authors.initials: J
authors.lastname: Gallarda
authors.affiliation: Critical Path Institute, Tucson, Arizona.
authors.forename: Debra
authors.initials: D
authors.lastname: Hanna
authors.affiliation: Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.
authors.forename: Peter S
authors.initials: PS
authors.lastname: Kim
authors.affiliation: Critical Path Institute, Tucson, Arizona.
authors.forename: Richard
authors.initials: R
authors.lastname: Liwski
authors.affiliation: Istituti di Ricovero e Cura a Carattere Scientifico, San Raffaele Scientific Institute, Milan, Italy.
authors.forename: Paolo
authors.initials: P
authors.lastname: Miotto
authors.affiliation: Critical Path Institute, Tucson, Arizona.
authors.forename: Marco
authors.initials: M
authors.lastname: Schito
authors.affiliation: Global TB Programme, TB Monitoring and Evaluation, World Health Organization, Geneva, Switzerland.
authors.forename: Matteo
authors.initials: M
authors.lastname: Zignol
mesh_terms: D000995:Antitubercular Agents; D004269:DNA, Bacterial / Q000235:genetics*; D030561:Databases, Nucleic Acid; D024881:Drug Resistance, Bacterial / Q000235:genetics; D005838:Genotype; D006801:Humans; D007391:International Cooperation; D009154:Mutation; D009169:Mycobacterium tuberculosis / Q000187:drug effects / Q000235:genetics*; D017422:Sequence Analysis, DNA; D014376:Tuberculosis / Q000175:diagnosis
chemical_list: D000995:Antitubercular Agents; D004269:DNA, Bacterial
keywords: Mycobacterium tuberculosis; database; drug resistance